| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2629 |
| Trial ID | NCT04806113 |
| Disease | COVID-19 | Rheumatoid Arthritis | Systemic Lupus Erythematosus |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Pfizer COVID-19 Vaccine|Moderna COVID-19 Vaccine |
| Location approved | US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Phase | Phase3 |
| Recruitment status | Completed |
| Title | COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases |
| Year | 2021 |
| Country | Canada |
| Company sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Other ID(s) | MP-37-2021-7562 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||